novo oral glp-1 Nordisk's Wegovy Pill Becomes First Available in U.S FDA approves first-ever oral GLP-1

A dose of 300 mg/kg substantially mitigated histopathological damage and DNA fragmentation in lung tissue (Tan et al., 2022)

Diverticular Disease and Additional Comorbidities Associated With Increased Risk of Dementia

The primary therapeutic indication for GLP-1 agonists in the UK is type 2 diabetes management, with some formulations also licensed for weight management

Targeting the microbiome in heart failure

After your first month of treatment, a simple genetic test ($99 add-on) provides data-driven insights to fine-tune your protocol for maximum results with minimal side effects

Neurosurgical Focus 38 , E10 (2015)